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The Society of Surgical Oncology (SSO) and its official journal, Annals of Surgical Oncology, have had a very important and successful partnership with the Japanese Society of Gastroenterological Surgery
(JSGS). As recent President of the SSO and now Editor-in-Chief of
Annals of Surgical Oncology, I would like to express our appreciation and gratitude for this longstanding relationship. This partnership has advanced our missions of promoting high-quality surgical science focused on improving patient outcomes.
Annals of Surgical Oncology is a global journal. It has a worldwide
readership and an international Editorial Board. It receives articles from all over the world. More than 10 000 institutions around the globe have access to Annals of Surgical Oncology. We expect that we will exceed 1 million article downloads this year, which reaches an enormous number of readers around the globe. 
The most prolific author in Annals of Surgical Oncology is Professor
Masaki Mori, who has also served on the Executive Council of SSO ( Figure 6 ). He has 76 publications which have been cited 1128 times.
We thank Professor Mori for his many contributions to the Journal and to the SSO.
The SSO strives to be the premier organization for surgeons dedicated to the multidisciplinary care of cancer patients and advancing the science, education, and practice of cancer surgery. We understand that, as cancer surgeons, despite all of the advances in chemotherapy, targeted therapy, immunotherapy, and radiation therapy, often the single best thing that we can do for our cancer patients is to carry out a good cancer operation. We have learned to carry out cancer surgery more safely, less invasively, and with less morbidity.
Yet, we know that surgery alone will not cure many of our patients because their disease has already progressed beyond what we can resect. That is why it is so important that we engage not only in research about surgical techniques, but we must also be involved in basic and translational research and development of adjuvant therapies, especially new targeted therapies and immunotherapies. This is what will allow us to improve patient outcomes and cure more patients in the future. The JSGS has been an important partner in advancing this research mission.
We believe that the SSO truly is a global society, and we are very interested in increasing our global outreach. The SSO now has over 575 international members across all categories. There are many active members from Japan and this number is growing, as we attract more and more members from around the world to join the SSO and attend the Annual Meeting.
The SSO now has a new learning management system, ExpertEd@ SSO, an online system that is going to continue to allow delivery of On behalf of the SSO and Annals of Surgical Oncology, thank you for the tremendous friendship and partnership between our organizations. We hope that this will only continue to grow stronger in the years ahead. 
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